Erythropoietin

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 3, 2013, Pages

  Bunn, H Franklin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR;

ANEMIA; CELL HYPOXIA; CHRONIC KIDNEY FAILURE; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HISTORY; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANEMIA; CELL HYPOXIA; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY FAILURE, CHRONIC; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; TRANSCRIPTION FACTORS;

EID: 84879001806     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011619     Document Type: Article

References (204)

1. Ang S.O., Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E., Sergueeva AI, Miasnikova GY, Mole D, et al. 2002. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614-621.
2. Arany Z., Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg M.A., Bunn HF, Livingston DM. 1996. Participation by the p300/CBP family of proteins in the cellular response to hypoxia. Proc Natl Acad Sci 93: 12969-12973.
3. Bachmann S., Le Hir M, Eckardt K. 1993. Co-localization of erythropoietin mRNA and ecto-50-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41: 335-341.
4. Bahlmann F.H., DeGroot K, Duckert T, Niemczyk E, Bahlmann E., Boehm SM, Haller H, Fliser D. 2003. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64: 1648-1652.
5. Bahlmann F.H., Song R, Boehm SM, Mengel M, von Wasielewski R., Lindschau C, Kirsch T, de Groot K, Laudeley R., Niemczyk E, et al. 2004. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin α persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110: 1006-1012.
6. Bazan JF. 1990. Haemopoietic receptors and helical cytokines. Immunol Today 11: 350-354.
7. Beall C.M., Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C., Li JC, Liang Y, McCormack M, et al. 2010. Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci 107: 11459-11464.
8. Beck I., Ramirez S, Weinmann R, Caro J. 1991. Enhancer element at the 30-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem 266: 15563-15566.
9. Bennett C.L., Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason K.J., Barnato SE, Elverman KM, Courtney DM, McKoy JM, et al. 2008. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924.
10. Berk L., Burchenal J, Wood TM, Castle W. 1948. Oxygen saturation of sternal marrow blood with special reference to pathogenesis of polycythemia vera. Proc Soc Exp Biol Med 69: 316-320.
11. Berra E., Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22: 4082-4090.
12. Berridge M.V., Fraser JK, Carter JM, Lin FK. 1988. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 72: 970-977.
13. Besarab A., Bolton WK, Browne JK, Egrie JC, Nissenson AR, OkamotoDM, Schwab SJ, GoodkinDA. 1998. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590.
14. Blanchard K.L., Acquaviva AM, Galson DL, Bunn HF. 1992. Hypoxic induction of the human erythropoietin gene: Cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 12: 5373-5385.
15. Bohlius J., Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J., Trelle S, Weingart O, Bayliss S, Djulbegovic B, et al. 2006. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708-714.
16. Boissel J-P, LeeW-R, Presnell SR, Cohen FE, Bunn HF. 1993. Erythropoietin structure-function relationships: Mutant proteins that test a model of tertiary structure. J Biol Chem 268: 15983-15993.
17. Brines M. 2010. The therapeutic potential of erythropoiesisstimulating agents for tissue protection: A tale of two receptors. Blood Purificat 29: 86-92.
18. Brines M.L., Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C., Itri LM, Cerami A. 2000. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci 97: 10526-10531.
19. Brines M., Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z., Erbayraktar S, Sepodes B, Thiemermann C, et al. 2008. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci 105: 10925-10930.
20. Bunn HF. 2007. New agents that stimulate erythropoiesis. Blood 109: 868-873.
21. Cario H., Schwarz K, Jorch N, Kyank U, Petrides PE, Schneider D.T., Uhle R, Debatin KM, Kohne E. 2005. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 90: 19-24.
22. Carnot P., Deflandre C. 1906. Sur l'activite hemopoietique des differents organeau au cours de la regeneration du sang. CR Searces Acad Sci 143: 432-435.
23. Caro J., Brown S, Miller O, Murray T, Erslev AJ. 1979. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93: 449-458.
24. Cheetham J.C., Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. 1998. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5: 861-866.
25. Chen Z.Y., Asavaritikrai P, Prchal JT, Noguchi CT. 2007. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 282: 25875-25883.
26. Chen J., Connor KM, Aderman CM, Smith LE. 2008. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 118: 526-533.
27. Clark D.A., Dessypris EN. 1986. Effects of recombinant erythropoietin on murine megakaryocytic colony formation in vitro. J Lab Clin Med 108: 423-429.
28. Cockman M.E., Masson N, Mole DR, Jaakkola P, Chang GW, Clifford S.C., Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. 2000. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
29. Cotes PM. 1989. Physiological studies of erythropoietin in plasma. In Erythropoietin (ed. Jelkmann W, Gross AJ), pp. 57-79. Springer, Berlin.
30. Dame C., Bartmann P, Wolber E, Fahnenstich H, HofmannD, Fandrey J. 2000. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res Dev Brain Res 125: 69-74.
31. Dame C., Sola MC, Lim KC, Leach KM, Fandrey J, Ma Y, Knopfle G., Engel JD, Bungert J. 2004. Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 279: 2955-2961.
32. Digicaylioglu M., Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C., Gassmann M. 1995. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci 92: 3717-3720.
33. Ebert B.L., Bunn HF. 1998. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and pp300/CREB binding protein. Mol Cell Biol 18: 4089-4096.
34. Ehrenreich H., Hasselblatt M, Dembowski C, Cepek L, Lewczuk P., Stiefel M, Rustenbeck HH, Breiter N, Jacob S., Knerlich F, et al. 2002. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495-505.
35. Ehrenreich H., Weissenborn K, Prange H, Schneider D, Weimar C., Wartenberg K, Schellinger PD, Bohn M, Becker H., Wegrzyn M, et al. 2009. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40: e647-e656.
36. Elliott S. 2008. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Brit J Pharmacol 154: 529-541.
37. Elliott S., Lorenzini T, Chang D, Barzilay J, Delorme E, Giffin J., Hesterberg L. 1996. Fine-structure epitope mapping of anti-erythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin protein structure. Blood 87: 2702-2713.
38. Elliott S., Lorenzini T, Chang D, Barzilay J, Delorme E. 1997. Mapping of the active site of recombinant human erythropoietin. Blood 89: 493-502.
39. Epstein A.C., Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson M.I., Dhanda A, et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
40. Erslev A. 1953. Humoral regulation of red cell production. Blood 8: 349-357.
41. Erslev A. 1980. Blood and mountains. In Blood, pure and eloquent (ed. Wintrobe M), pp. 256-280. McGraw Hill, New York.
42. Erslev AJ. 1993. The discovery of erythropoietin. ASAIO J 39: 89-92.
43. Erslev A.J., Caro J. 1984. Pure erythrocytosis classified according to erythropoietin titers. Am J Med 76: 57-61.
44. Erslev A.J., Caro J, Besarab A. 1985. Why the kidney?Nephron 41: 213-216.
45. Erslev A.J., Wilson J, Caro J. 1987. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med 109: 429-433.
46. Eschbach J.W., Ergie JC, Downing MR, Browne JK, Adamson JW. 1987. Correction of the anemia of endstage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73-78.
47. Fandrey J. 2004. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286: R977-R988.
48. Fiordaliso F., Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I., Doni M, Mengozzi M, Tonelli R, Ghezzi P, et al. 2005. A nonerythropoietic derivative of erythropoietin protects themyocardium from ischemia-reperfusion injury. Proc Natl Acad Sci 102: 2046-2051.
49. Fischl M., Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P., Miles S, Robbins W, Starrett B, Zalusky R, et al. 1990. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322: 1488-1493.
50. Fox HM. 1947. Daphnia haemoglobin. Nature 160: 431.
51. Fox HM. 1949. Haemoglobin in Crustacea. Nature 164: 59.
52. Frede S., Freitag P, Geuting L, Konietzny R, Fandrey J. 2011. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 117: 4905-4914.
53. FriedW, Plzak L, Jacobson L, Goldwasser E. 1956. Studies on erythropoiesis II. Assay of erythropoietin in hypophysectomized rats. Proc Soc Exp Biol Med 92: 203-207.
54. Furlow P.W., Percy MJ, Sutherland S, Bierl C, McMullin MF, Master S.R., Lappin TR, Lee FS. 2009. Erythrocytosisassociated HIF-2α mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem 284: 9050-9058.
55. Gale D.P., Harten SK, ReidCD, TuddenhamEG, Maxwell PH. 2008. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 α mutation. Blood 112: 919-921.
56. Galson D.L., Tsuchiya T, Tendler DS, Huang LE, Ren Y, Ogura T., Bunn HF. 1995. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoetin gene expression and is antagonized by EAR3/COUPTF1. Mol Cell Biol 15: 2135-2144.
57. Gnarra J.R., Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E., Oldfield EH, KlausnerRD, LinehanWM. 1996. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci 93: 10589-10594.
58. Goldberg M.A., Glass GA, Cunningham JM, Bunn HF. 1987. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci 84: 7972-7976.
59. Goldwasser E. 1996. Erythropoietin, a somewhat personal history. Perspect Biol Med 40: 18-32.
60. Goldwasser E., Kung CK-H, Eliason J. 1974. On the mechanism of erythropoietin-induced differentiation. J Biol Chem 249: 4202-4206.
61. Gordeuk V.R., Prchal JT. 2006. Vascular complications in Chuvash polycythemia. Semin Thromb Hemost 32: 289-294.
62. Gorr T.A., Cahn JD, Yamagata H, Bunn HF. 2004. Hypoxiainduced synthesis of hemoglobin in the crustacean Daphnia magna is hypoxia-inducible factor-dependent. J Biol Chem 279: 36038-36047.
63. Gradin K., McGuire J, Wenger RH, Kvietikova I, WhitelawM, Toftgard R., Tora L, Gassman M, Poellinger L. 1996. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16: 5221-5231.
64. Grant W.C., Root WS. 1952. Fundamental stimulus for erythropoiesis. Physiol Rev 32: 449-498.
65. Gruber M., Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. 2007. Acute postnatal ablation of Hif-2α results in anemia. Proc Natl Acad Sci 104: 2301-2306.
66. Gu Y.Z., Moran SM, Hogenesch JB, Wartman L, Bradfield CA. 1998. Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α. Gene Expr 7: 205-213.
67. Heeschen C., Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C., Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. 2003. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340-1346.
68. Henke M., Laszig R, Rube C, Schafer U, Haase KD, Schilcher B., Mose S, Beer KT, Burger U, Dougherty C, et al. 2003. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260.
69. Hermine O., Beru N, Pech N, Goldwasser E. 1991. An autocrine role for erythropoietin in mouse hematopoietic cell differentiation. Blood 78: 2253.
70. Hickey M.M., Lam JC, Bezman NA, Rathmell WK, Simon MC. 2007. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2α signaling and splenic erythropoiesis. J Clin Invest 117: 3879-3889.
71. Hoffman E.C., Reyes H, Chu F-F, Sander F, Conley LH, Brooks B.A., Hankinson O. 1991. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252: 954-958.
72. Horiguchi H., Kayama F, Oguma E, Willmore WG, Hradecky P., Bunn HF. 2000. Cadmium and platinum suppression of erythropoietin production in cell culture. Blood 96: 3743-3747.
73. Hu B., Wright E, Campbell L, Blanchard KL. 1997. In vivo analysis of DNA-protein interactions on the human erythropoietin enhancer. Mol Cell Biol 17: 851-856.
74. Huang L.E., Arany Z, Livingston DM, Bunn HF. 1996. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its a subunit. J Biol Chem 271: 32253-32259.
75. Huang L.E., Gu J, Schau M, Bunn HF. 1998. Regulation of hypoxia-inducible factor 1α is mediated by an oxygendependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 95: 7987-7992.
76. Iliopoulos O., Levy AP, Jiang CWG, Kaelin J, Goldberg MA. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci 93: 10595-10599.
77. Imagawa S., Izumi T, Miura Y. 1994. Positive and negative regulation of the erythropoietin gene. J Biol Chem 269: 9038-9044.
78. Imagawa S., Yamamoto M, Miura Y. 1997. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 89: 1430-1439.
79. 2 sensing. Science 292: 464-468.
80. Ivan M., Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway J.W., et al. 2002. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci 99: 13459-13464.
81. 2homeostasis by hypoxia-inducible factor 1α. Genes Dev 12: 149-162.
82. Jaakkola P., Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell S.J., Kriegsheim A, Hebestreit HF, Mukherji M, Schofield C.J., et al. 2001. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
83. Jacobs K., Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch E.F., et al. 1985. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806-810.
84. Jacobson L.O., Marks E, Gaston E, Goldwasser E. 1957. Role of the kidney in erythropoiesis. Nature 179: 633-634.
85. JelkmannW. 1992. Erythropietin: Structure, control of production, and function. Physiol Rev 72: 449-489.
86. Jelkmann W. 2005. Effects of erythropoietin on brain function. Curr Pharm Biotechnol 6: 65-79.
87. Jelkmann W. 2008. Developments in the therapeutic use of erythropoiesis stimulating agents. Brit J Haematol 141: 287-297.
88. Jelkmann W., Wagner K. 2004. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83: 673-686.
89. Kapitsinou P.P., Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein J.A., Moores SL, Erickson-Miller CL, Haase VH. 2010. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116: 3039-3048.
90. Koury M.J., Bondurant MC. 1990. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248: 378-381.
91. Koury S.T., Bondurant MC, Koury MJ. 1988. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71: 524-527.
92. Koury S.T., Koury MJ, Bondurant MC, Caro J, Graber SE. 1989. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: Correlationwith hematocrit, renal erythopoietin mRNA, and serum erythropoietin concentration. Blood 74: 645-651.
93. Koury S.T., Bondurant MC, Koury MJ, Semenza GL. 1991. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77: 2497-2503.
94. Krumdieck N. 1943. Erythropoietic substance in the serum of anemic animals. Proc Soc Exp Biol Med 54: 14-17.
95. Lacombe C., Silva J-LD, Bruneval P, Fournier J-G, Wendling F, Casadevall N, Camilleri J-P, Bariety J, Varet B, Tambourin P. 1988. Pertubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81: 620-623.
96. Ladroue C., Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouyssegur J, Richard S, Gardie B. 2008. PHD2 mutation and congenital ery-throcytosis with paraganglioma. N Engl J Med 359: 2685-2692.
97. La Ferla K, Reimann C, JelkmannW, Hellwig-Burgel T. 2002. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. FASEB J 16: 1811-1813.
98. Lando D., Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. 2002a. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471.
99. Lando D., Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. 2002b. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861.
100. Leist M., Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C., Bianchi M, Nielsen J, Gerwien J, et al. 2004. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242.
101. Le Minh K, Klemm K, Abshagen K, Eipel C, Menger MD, Vollmar B. 2007. Attenuation of inflammation and apoptosis by pre-and posttreatment of darbepoetin-α in acute liver failure of mice. Am J Pathol 170: 1954-1963.
102. Leyland-Jones B. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460.
103. Lin F-K, Suggs S, Lin C-H, Browne JK, Smalling R, Egrie JC, Chen K.K., Fox GM, Martin F, Stabinsky Z, et al. 1985. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 82: 7580-7584.
104. Livnah O., Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA. 1996. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science 273: 464-471.
105. Livnah O., Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. 1999. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283: 987-990.
106. Macdougall IC. 2005. CERA (Continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4: 436-440.
107. Macdougall I.C., Robson R, Opatrna S, Liogier X, Pannier A, Jordan P., Dougherty FC, Reigner B. 2006. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1: 1211-1215.
108. Madan A., Lin C, Hatch SL, Curtin PT. 1995. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 85: 2735-2741.
109. Mahon P.C., Hirota K, Semenza GL. 2001. FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686.
110. Makita T., Hernandez-Hoyos G, Chen TH, Wu H, Rothenberg EV, Sucov HM. 2001. A developmental transition in definitive erythropoiesis: Erythropoietin expression is sequentially regulated by retinoic acid receptors and HNF4. Genes Dev 15: 889-901.
111. Marti H.H., Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M. 1996. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8: 666-676.
112. Martini M., Teofili L, Cenci T, Giona F, Torti L, Rea M, Foa R, Leone G., Larocca LM. 2008. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 93: 1068-1071.
113. Masson N., Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206.
114. Masuda S., Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. 1994. A novel site of erythropoietin production: Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269: 19488-19493.
115. Maxwell P.H., Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJP, Johnson MH, Ratcliffe PJ. 1993a. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44: 1149-1162.
116. Maxwell P.H., Pugh CW, Ratcliffe PJ. 1993b. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci 90: 2423-2427.
117. Maxwell P.H., Ferguson DJP, Osmond MK, Pugh CW, Heryet A., Doe BG, Johnson MH, Ratcliffe PJ. 1994. Expression of a homologously recombined erythopoietin-SV40 Tantigen fusion gene in mouse liver: Evidence for erythropoietin production by Ito cells. Blood 84: 1823-1830.
118. Maxwell P.H., Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
119. McDonald TP, Cottrell MB, Clift RE, Cullen WC, Lin FK. 1987. High doses of recombinant erythropoietin stimulate platelet production in mice. Exp Hematol 15: 719-721.
120. McLeod DL, Shreeve MM, Axelrad AA. 1974. Improved plasma culture system for production of erythrocytic colonies in vitro: Quantitative assay method for CFU-E. Blood 44: 517-534.
121. Means RT Jr. 1994. Clinical application of recombinant erythropoietin in the anemia of chronic disease. Hematol Oncol Clin North Am 8: 933-944.
122. Messinezy M., Westwood NB, El-Hemaidi I, Marsden JT, Sherwood R.S., Pearson TC. 2002. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Brit J Haematol 117: 47-53.
123. Miescher F. 1893. Ü ber die Beziehungen zwischen Meereshöhe und Beschaffenheit des Blutes. Corresp Bl Schweiz Aerzte 23: 809-830.
124. Miller C.B., Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. 1990. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689-1692.
125. Minamishima Y.A., Moslehi J, Bardeesy N, Cullen D, Bronson R.T., Kaelin WG Jr. 2008. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111: 3236-3244.
126. Miyake T., Hung CKH, Goldwasser E. 1977. Purification of human erythropoietin. J Biol Chem 252: 5558-5564.
127. Mohyeldin A., Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A. 2005. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7: 537-543.
128. Nathan D.G., Schupak E, Stohlman F Jr, Merrill JP. 1964. Erythropoiesis in anephric man. J Clin Invest 43: 2158-2165.
129. Nishiya D., Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M. 2006. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharm Sci 101: 31-39.
130. Noguchi C.T., Asavaritikrai P, Teng R, Jia Y. 2007. Role of erythropoietin in the brain. Crit Rev Oncol Hemat 64: 159-171.
131. Noguchi C.T., Wang L, Rogers HM, Teng R, Jia Y. 2008. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 10: e36.
132. Obara N., Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. 2008. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111: 5223-5232.
133. Ohh M., Park CW, Ivan M, Hoffman MA, Kim TY, Huang L.E., Pavletich N, Chau V, KaelinWG. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
134. Paliege A., Rosenberger C, Bondke A, Sciesielski L, Shina A, HeymanSN, Flippin LA, Arend M, Klaus SJ, Bachmann S. 2010. Hypoxia-inducible factor-2α-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 77: 312-318.
135. Parsa C.J., Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski J.A., Matsumoto A, Stamler JS, Koch WJ. 2004. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem 279: 20655-20662.
136. Pastore Y.D., Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, Krishnamurti L., Prchal JT. 2003. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101: 1591-1595.
137. Patel N.S., Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob M.M., Thiemermann C. 2004. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/ reperfusion in the mouse kidney in vivo. Kidney Int 66: 983-989.
138. Percy M.J., Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell P.H., McMullin MF, Lee FS. 2006. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci 103: 654-659.
139. Percy M.J., Furlow PW, Beer PA, Lappin TR, McMullin MF, Lee FS. 2007. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 110: 2193-2196.
140. Percy M.J., Beer PA, Campbell G, Dekker AW, Green AR, Oscier D., Rainey MG, vanWijk R, Wood M, Lappin TR, et al. 2008a. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 111: 5400-5402.
141. Percy M.J., Furlow PW, Lucas GS, Li X, Lappin TR, Mc-Mullin M.F., Lee FS. 2008b. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358: 162-168.
142. Percy M.J., Chung YJ, Harrison C, Mercieca J, Hoffbrand VJ, Dinardo C.L., Dantos PCJL, Fonseca GHH, Gualalndro SFM, Pereira AC, et al. 2012. Two new mutations in the HIF2A gene associated with erythrocytosis. Am J Hematol 87: 439-442.
143. Perrotta S., Nobili B, Ferraro M, Migliaccio C, Borriello A, Cucciolla V., Martinelli V, Rossi F, Punzo F, Cirillo P, et al. 2006. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: Identification of a novel cluster. Blood 107: 514-519.
144. Peyssonnaux C., Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S., Haase VH, Nizet V, Johnson RS. 2007. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117: 1926-1932.
145. Phrommintikul A., Haas SJ, Elsik M, Krum H. 2007. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369: 381-388.
146. Prchal J.F., Prchal JT. 1999. Molecular basis for polycythemia. Curr Opin Hematol 6: 100-109.
147. Provenzano R., Besarab A, Macdougall IC, Ellison DH, Maxwell A.P., Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R., Dougherty FC. 2007. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol 67: 306-317.
148. Pugh C.W., Tan CC, Jones RW, Ratcliffe PJ. 1991. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc Natl Acad Sci 88: 10553-10557.
149. Pugh C.W., Ebert BL, Ebrahim O, Ratcliffe PJ. 1994. Characterisation of functional domains within the mouse erythropoietin 3′ enhancer conveying oxygen-regulated responses in different cell lines. Biochem Biophys Acta 1217: 297-306.
150. Rankin E.B., Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon M.C., Keith B, Haase VH. 2007. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068-1077.
151. Reissmann KR. 1950. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 5: 372-380.
152. Remy I., Wilson IA, Michnick SW. 1999. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283: 990-993.
153. Rosa R., Prehu M-O, Beuzard Y, Rosa J. 1978. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest 62: 907.
154. Ruhenstroth-Bauer G. 1950. Versuche zum Nachweis eines spezifischen erythropetischen Hormons. Arch Exp Pathol Pharmakol 211: 32-56.
155. Ryan H.E., Lo J, Johnson RS. 1998. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015.
156. Safran M., Kim WY, O'Connell F, Flippin L, Gunzler V, Horner J.W., Depinho RA, Kaelin WG Jr. 2006. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci 103: 105-110.
157. Sakanaka M., Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M., Sasaki R. 1998. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci 95: 4635-4640.
158. Salceda S., Caro J. 1997. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647.
159. Schmeding M., Boas-Knoop S, Lippert S, Ruehl M, Somasundaram R., Dagdelen T, Neuhaus P, Neumann UP. 2008. Erythropoietin promotes hepatic regeneration after extended liver resection in rats. J Gastroenterol Hepatol 23: 1125-1131.
160. Schmeding M., Hunold G, Ariyakhagorn V, Rademacher S, Boas-Knoop S, Lippert S, Neuhaus P, NeumannUP. 2009. Erythropoietin reduces ischemia-reperfusion injury after liver transplantation in rats. Transpl Int 22: 738-746.
161. Schmid T.C., Loffing J, Le Hir M, Kaissling B. 1994. Distribution of ecto-50-nucleotidase in the rat liver: Effect of anaemia. Histochemistry 101: 439-447.
162. Schuster S.J., Koury ST, Bohrer M, Salceda S, Caro J. 1992. Cellular sites of extrarenal and renal erythropoietin production in anemic rats. Brit J Hematol 81: 153-159.
163. Scortegagna M., Ding K, Zhang Q, Oktay Y, Bennett MJ, Bennett M., Shelton JM, Richardson JA, Moe O, Garcia JA. 2005. HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105: 3133-3140.
164. Semenza G.L., Wang GL. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454.
165. Semenza G.L., Trystman M, Gearhart JD, Antonarakis S. 1989. Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl Acad Sci 86: 2301-2305.
166. SemenzaGL, DurezaRC, TraystmanMD, Gearhart JD, Antonarakis SE. 1990. Human erythropoietin gene expression in transgenic mice:Multiple transcription initiation sites and cis-acting regulatory elements. Mol Cell Biol 10: 930-938.
167. Semenza G.L., Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. 1991a. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci 88: 8725-8729.
168. Semenza G.L., Nejfelt MK, Chi SM, Antonarakis SE. 1991b. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci 88: 5680-5684.
169. Sepodes B., Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, Thiemermann C, Mota-Filipe H. 2006. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 19: 919-926.
170. Sergeyeva A., Gordeuk VR, Tokarev YN, Sokol L, Prchal JH, Prchal JT. 1997. Congenital polycythemia in Chuvashia. Blood 89: 2148-2154.
171. Sharples E.J., Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M., Kieswich J, Allen D, Harwood S, Raftery M, et al. 2004. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124.
172. Simonson T.S., Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, et al. 2010. Genetic evidence for high-altitude adaptation in Tibet. Science 329: 72-75.
173. Sinclair A.M., Rogers N, Busse L, Archibeque I, Brown W, Kassner P.D., Watson JE, Arnold GE, Nguyen KC, Powers S, et al. 2008. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Brit J Cancer 98: 1059-1067.
174. Singh A., Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, Kurtz A, Reinhart WH. 1993. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91: 251-256.
175. Singh A.K., Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. 2006. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098.
176. Spivak JL. 1994. Recombinant human erythropoietin and the anemia of cancer [editorial]. Blood 84: 997-1004.
177. Stohlman F.J., Rath C, Rose J. 1954. Evidence for a humoral regulation of erythropoiesis. Blood 9: 721-733.
178. Stopka T., Zivny JH, Stopkova P, Prchal JF, Prchal JT. 1998. Human hematopoietic progenitors express erythropoietin. Blood 91: 3766-3772.
179. Suzuki N., Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T., Imagawa S, Yamamoto M. 2002. Erythroidspecific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100: 2279-2288.
180. Syed R.S., Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H., Osslund TD, Chirino AJ, Zhang J, et al. 1998. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395: 511-516.
181. Takeda K., Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ, Takeda H., Lee FS, Fong GH. 2008. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 111: 3229-3235.
182. Tan C.C., Eckardt K-U, Ratcliffe PJ. 1991. Organ distribution of erythopoietin messenger RNA in normal and uremic rats. Kidney Int 40: 69-76.
183. Tian H., McKnight SL, Russell DW. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82.
184. Tsai P.T., Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, Liu X., Wu H, Carmichael ST. 2006. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 26: 1269-1274.
185. van Wijk R, Sutherland S, Van Wesel AC, Huizinga EG, Percy M.J., Bierings M, Lee FS. 2010. Erythrocytosis associatedwith a novel missense mutation in the HIF2A gene. Haematologica 95: 829-832.
186. Vaziri N.D., Zhou XJ, Liao SY. 1994. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266: F360-F366.
187. Viault F. 1890. Sur l'augmentation considerable du nombre des globules rouges dans le sang chez les habitants des hautes plateaux de l'Amerique du sud. CR Acad Sci Paris 111: 918-919.
188. Volke M., Gale DP, Maegdefrau U, Schley G, Klanke B, Bosserhoff A.K., Maxwell PH, Eckardt KU, Warnecke C. 2009. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PloS ONE 4: e7875.
189. Wang G.L., Semenza GL. 1993a. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 82: 3610-3615.
190. Wang G.L., Semenza GL. 1993b. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci 90: 4304-4308.
191. Wang G.L., Semenza GL. 1995. Purification and characterization of hypoxia-inducible factor-1. J Biol Chem 270: 1230-1237.
192. 2tension. Proc Natl Acad Sci 92: 5510-5514.
193. Wang G.L., Jiang BH, Rue EA, Semenza GL. 1995b. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci 92: 5510-5514.
194. Warnecke C., Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M., Eckardt KU. 2004. Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J 18: 1462-1464.
195. Wen D., Boissel J-P, Showers M, Ruch BC, Bunn HF. 1994. Erythropoietin structure-function relationships: Identification of functionally important domains. J Biol Chem 269: 22839-22846.
196. Wenger R.H., Kurtz A. 2011. Erythropoietin. Compr Physiol 1: 1759-1794.
197. Wenger R.H., Stiehl DP, Camenisch G. 2005. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12.
198. Wood S.M., Gleadle JM, PughCW, HankinsonO, Ratcliffe PJ. 1996. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. J Biol Chem 269: 15117-15123.
199. Wrighton N.C., Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe L.K., Dower WJ. 1996. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458-463.
200. Yamaji R., Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y. 1996. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239: 494-500.
201. Yan L., Colandrea VJ, Hale JJ. 2010. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: Small molecule-based therapeutics for anemia. Expert Opin Ther Pat 20: 1219-1245.
202. Yang C.W., Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim Y.S., Kim J, Chang YS, et al. 2003. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17: 1754-1755.
203. Yi X., Liang Y, Huerta-Sanchez E, Jin X, Cuo ZX, Pool JE, Xu X., Jiang H, Vinckenbosch N, Korneliussen TS, et al. 2010. Sequencing of 50 human exomes reveals adaptation to high altitude. Science 329: 75-78.
204. Yu F., White SB, Zhao Q, Lee FS. 2001. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci 98: 9630-9635.